Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 27, 2009Arthritis Care & ResearchOpen Access

A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDaniel J. WallaceCedars-Sinai Medical CenterWSWilliam StohlUniversity of Southern CaliforniaRFRichard FurieNorthwell Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wallace et al. (2009) studied this question.

synapsesocial.com/papers/6a6ff60e31a3df824328422ahttps://doi.org/10.1002/art.24699
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels2005 · 150 citations
  2. 2BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact2008 · 176 citations
  3. 3Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases2001 · 805 citations
  4. 4Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus2001 · 733 citations
  5. 5BAFF selectively enhances the survival of plasmablasts generated from human memory B cells2003 · 506 citations